Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 15;26(2):107-117.
doi: 10.7499/j.issn.1008-8830.2309059.

[Clinical practice guidelines for meropenem therapy in neonatal sepsis (2024)]

[Article in Chinese]

[Clinical practice guidelines for meropenem therapy in neonatal sepsis (2024)]

[Article in Chinese]
Guideline Development Group of Clinical Practice Guidelines for Meropenem Therapy in Neonatal Sepsis; PekingUniversity Third Hospital; Editorial Department of Chinese Journal of Contemporary Pediatrics. Zhongguo Dang Dai Er Ke Za Zhi. .

Abstract

Meropenem is one of the most widely used special-grade antimicrobial agents in the treatment of neonatal sepsis. However, its irrational use has led to an increasingly severe problem of bacterial multidrug resistance. The guideline was developed following standardized methods and procedures, and provides 12 recommendations specifically addressing 9 clinical issues. The recommendations cover various aspects of meropenem use in neonates, including timing of administration, recommended dosage, extended infusion, monitoring and assessment, antimicrobial adjustment strategies, treatment duration, and treatment strategies for carbapenem-resistant Enterobacteriaceae infections. The aim of the guideline is to provide evidence-based recommendations and guidance for the rational use of meropenem in neonates with sepsis.

美罗培南是新生儿脓毒症治疗中使用最为广泛的特殊级别抗菌药物之一,但其不合理应用导致细菌多重耐药问题日益严峻。该指南遵循规范的制订方法与流程,针对9个临床问题形成了12条推荐意见,内容涵盖新生儿美罗培南的使用时机、推荐剂量、延长输注、监测与评估、抗菌药物调整方案、治疗疗程以及碳青霉烯耐药肠杆菌目细菌感染的治疗策略,以期为美罗培南在新生儿脓毒症患儿中的合理使用提供循证证据与用药建议。.

Keywords: Clinical practice guideline; Meropenem; Neonate; Sepsis.

PubMed Disclaimer

Conflict of interest statement

本指南的制订受到了国家重点研发计划(2021YFC2700700)和国家自然科学基金项目(72304008)的资助,其资金主要用于指南制订会议和制订组专家的劳务支出。本指南形成的推荐意见未受到资助的影响。指南制订组所有成员均声明无利益冲突。

Similar articles

Cited by

References

    1. Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, et al. . The global burden of paediatric and neonatal sepsis: a systematic review[J]. Lancet Respir Med, 2018, 6(3): 223-230. DOI: 10.1016/S2213-2600(18)30063-8. - DOI - PubMed
    1. Zhanel GG, Wiebe R, Dilay L, et al. . Comparative review of the carbapenems[J]. Drugs, 2007, 67(7): 1027-1052. DOI: 10.2165/00003495-200767070-00006. - DOI - PubMed
    1. Prusakov P, Goff DA, Wozniak PS, et al. . A global point prevalence survey of antimicrobial use in neonatal intensive care units: the no-more-antibiotics and resistance (NO-MAS-R) study[J]. EClinicalMedicine, 2021, 32: 100727. DOI: 10.1016/j.eclinm.2021.100727. - DOI - PMC - PubMed
    1. 徐晓涵, 周鹏翔, 孔旭东, 等. 北京市医疗机构抗菌药物临床应用分级管理目录的循证制订[J]. 中国药学杂志, 2023, 58(2): 188-194. DOI: 10.11669/cpj.2023.02.014. - DOI
    1. 童笑梅, 周鹏翔. 优化新生儿重症监护病房抗生素管理: 遏制耐药菌泛滥趋势[J]. 中华新生儿科杂志, 2021, 36(5): 1-5. DOI: 10.3760/cma.j.issn.2096-2932.2021.05.001. - DOI

Publication types